Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CCR5 | P51681 | 8/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.36 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3920468 | 0.89 | HSD11B1 (0.46) | GAATSHRHTTSMN1; SMN2CCR5 | |
| SCHEMBL3919295 | 0.83 | KMT2A (0.45) | TSHRHTTCCR5MEN1KMT2A | |
| SCHEMBL3925589 | 0.83 | MEN1 (0.44) | GAASMN1; SMN2CCR5MEN1KMT2A | |
| SCHEMBL3918743 | 0.80 | ALDH1A1 (0.38) | GAATSHRHTTSMN1; SMN2HSD11B1 | |
| SCHEMBL3915453 | 0.79 | HSD11B1 (0.48) | GAATSHRHTTSMN1; SMN2HSD11B1 | |
| SCHEMBL3917724 | 0.78 | CYP2D6 (0.51) | GAATSHRHTTSMN1; SMN2MEN1 | |
| SCHEMBL3925408 | 0.78 | SMN1; SMN2 (0.48) | GAATSHRHTTSMN1; SMN2MEN1 | |
| SCHEMBL4034055 | 0.78 | L3MBTL1 (0.45) | GAATSHRHTTMEN1KMT2A | |
| SCHEMBL4041277 | 0.77 | KMT2A (0.41) | GAATSHRHTTSMN1; SMN2HSD11B1 | |
| SCHEMBL3919576 | 0.77 | MMP2 (0.51) | GAATSHRHTTSMN1; SMN2HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7560468-B2 | Substituted 1,4,8-triazaspiro[4,5]decan-2-one compounds | GRUENENTHAL GMBH (DE) | 2009-07-14 | — | — | US | claimed |
| EP-1730144-B1 | SUBSTITUTED 1,4,8-TRIAZASPIRO¬4.5 DECAN-2-ONE COMPOUNDS | GRUENENTHAL GMBH (DE) | 2009-06-10 | — | — | EP | claimed |
| US-20070015783-A1 | Substituted 1,4,8-triazaspiro[4,5]decan-2-one compounds | GRUENENTHAL GMBH (DE) | 2007-01-18 | — | — | US | claimed |
| EP-1730144-A1 | SUBSTITUTED 1,4,8-TRIAZASPIRO¬4.5|DECAN-2-ONE COMPOUNDS | Grünenthal GmbH (DE) | 2006-12-13 | — | — | EP | claimed |
| WO-2005095398-A1 | SUBSTITUTED 1,4,8-TRIAZASPIRO[4.5]DECAN-2-ONE COMPOUNDS | Grünenthal GmbH (DE) | 2005-10-13 | — | — | WO | claimed |
| US-7560468-B2 | Substituted 1,4,8-triazaspiro[4,5]decan-2-one compounds | GRUENENTHAL GMBH (DE) | 2009-07-14 | — | — | US | disclosed |
| EP-1730144-B1 | SUBSTITUTED 1,4,8-TRIAZASPIRO¬4.5 DECAN-2-ONE COMPOUNDS | GRUENENTHAL GMBH (DE) | 2009-06-10 | — | — | EP | disclosed |
| US-20070015783-A1 | Substituted 1,4,8-triazaspiro[4,5]decan-2-one compounds | GRUENENTHAL GMBH (DE) | 2007-01-18 | — | — | US | disclosed |
| EP-1730144-A1 | SUBSTITUTED 1,4,8-TRIAZASPIRO¬4.5|DECAN-2-ONE COMPOUNDS | Grünenthal GmbH (DE) | 2006-12-13 | — | — | EP | disclosed |
| WO-2005095398-A1 | SUBSTITUTED 1,4,8-TRIAZASPIRO[4.5]DECAN-2-ONE COMPOUNDS | Grünenthal GmbH (DE) | 2005-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015783-A1 | Substituted 1,4,8-triazaspiro[4,5]decan-2-one compounds | THPO, UGT1A8, UGT1A4 | GAA 79/4885TSHR 1408/4885HTT 509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.